Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Bleomycin pharmacokinetics in man

II. Intracavitary administration


Disposition of bleomycin was studied in plasma and urine (14 patients) and ascites fluid (2 patients) after intraperitoneal (IP) and intrapleural (IPl) administration, by radioimmunoassay. Peak plasma bleomycin concentrations after 60 U/m2 in 12 patients ranged between 0.4 and 5.0 mU/ml. For those patients with creatinine clearances greater than 50 ml/min the composite terminal phase bleomycin plasma half-lives (±SD) for three ‘IPl’ and six ‘IP’ patients were 3.4±0.3 and 5.3±0.4 h, respectively. The composite IP plasma half-life was significantly longer than the IPl hal-life (P<0.001) and previously reported IV half-life (t1/2=4.0 ±0.6 h) (P<0.01). In patients with normal renal function, bleomycin excretion during the first 24 h was in most cases lower following intracavitary (IC) than following IV administration (21.7%±8.6% vs. 44.8%±12.6%, respectively) (P<0.005). Comparison of bleomycin plasma concentration time products normalized for dose and half-life for IV and IC administration allowed an estimate that about 45% of the IC bleomycin dosage is absorbed into the systemic circulation. When calculating the total systemic exposure to bleomycin for a patient we suggest using the sum of the IV dose and one-half of the IC dose.

This is a preview of subscription content, log in to check access.


  1. 1.

    Alberts, D. S., Chen, H.-S. G., Liu, R., Chen, J., Mayersohn, M., Perrier, D., Moon, T., Gross, J., Broughton, A., Salmon, S.: Systemic absorption of bleomycin after intracavitary administration. Proc. ASCO and AACR 19, 305 (1978)

  2. 2.

    Alberts, D. S., Chen, H.-S. G., Liu, R., Himmelstein, K. J., Mayersohn, M., Perrier, D., Gross, J., Moon, T., Broughton, A., Salmon, S. E.: Bleomycin pharmacokinetics in man, I. Intravenous administration. Cancer Chemother. Pharmacol. 1, 177 (1978)

  3. 3.

    Blum, R. H., Carter, S. K., Agre, K.: A clinical review of bleomycin — a new antineoplastic agent. Cancer 31, 903 (1972)

  4. 4.

    Boxebaum, H. G., Riegelman, S., Elashoff, R. M.: Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2, 123 (1974)

  5. 5.

    Broughton, A., Strong, J. E.: Radioimmunoassay of bleomycin. Cancer Res. 36, 1430 (1977)

  6. 6.

    Dedrick, R. L., Myers, C. E., Bungay, P. M., DeVita, V. T.: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1 (1978)

  7. 7.

    Mawer, G. E., Knowles, B. R., Lucas, S. B., Stirland, R. M., Tooth, J. A.: Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972 I, 12

  8. 8.

    Metzler, C. M.: Technical Report 7292/69/7292/005. Kalamazoo, Mich.: Upjohn Co. 1969

  9. 9.

    Paladine, W., Cunningham, T. J., Sponzo, R., Donavan, M., Olson, K., Horton, J.: Intracavitary bleomycin in the management of malignant effusion. Cancer 38, 1903 (1976)

  10. 10.

    Sedman, A. J., Wagner, J. G.: CSTRIP. A Fortran IV computer program for obtaining initial polyexponential parameter estimates. J. Pharm. Sci. 65, 1006 (1976)

Download references

Author information

Correspondence to D. S. Alberts.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Alberts, D.S., Chen, H.G., Mayersohn, M. et al. Bleomycin pharmacokinetics in man. Cancer Chemother. Pharmacol. 2, 127–132 (1979).

Download citation


  • Creatinine Clearance
  • Bleomycin
  • Peak Plasma
  • Normal Renal Function
  • Systemic Exposure